The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma

被引:31
作者
Jones, D
Fletcher, CDM
Pulford, K
Shahsafaei, A
Dorfman, DM
机构
[1] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Div Hematopathol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Univ Oxford, John Radcliffe Hosp, Dept Cellular Sci, Immunodiagnost Unit,Leukemia Res Fund, Oxford OX3 9DU, England
关键词
D O I
10.1182/blood.V93.10.3487.410k39_3487_3493
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The tumor necrosis factor (TNF) receptor family includes several important markers of activation in T cells. We examined expression patterns of two T-cell-associated members of these receptors, namely CD30 and OX40/CD134, in 148 cases of T-cell lymphoma to identify possible objective immunohistochemical criteria for subclassification of these tumors. CD30 expression was characteristic of tumors with an anaplastic (46/47 cases [98%]) or large-cell (10/21 [48%]) morphology and was seen in only scattered cells in other tumor types, In contrast, large numbers of OX40/CD134(+) tumors cells were typical of angioimmunoblastic lymphoma (15/16 [94%]), angiocentric lymphoma (4/4), a subset of large-cell lymphomas (10/21 [48%]), and lymphomas with a prominent histiocytic component (6/7 [86%]). Strong OX40/ CD134 and CD30 coexpression was seen in only 4% of tumors, typically those with an anaplastic/Hodgkin's-like appearance. OX40/CD134 expression was characteristic of tumors composed of activated CD4(+) T cells and was not seen in small-cell T-cell lymphomas, lymphoblastic lymphomas, or other tumor types, including B-cell lymphomas or carcinomas. These results suggest that immunostaining for OX40/CD134 may be helpful in subclassification of peripheral T-cell lymphomas and that the patterns of TNF receptor family expression in these tumors may parallel those seen within nonneoplastic helper T-cell subsets. (C) 1999 by The American Society of Hematology.
引用
收藏
页码:3487 / 3493
页数:7
相关论文
共 55 条
[41]  
2-C
[42]   CD30 EXPRESSION IN NON-HODGKINS-LYMPHOMA [J].
PIRIS, M ;
BROWN, DC ;
GATTER, KC ;
MASON, DY .
HISTOPATHOLOGY, 1990, 17 (03) :211-218
[43]   Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1 [J].
Pulford, K ;
Lamant, L ;
Morris, SW ;
Butler, LH ;
Wood, KM ;
Stroud, D ;
Delsol, G ;
Mason, DY .
BLOOD, 1997, 89 (04) :1394-1404
[44]   The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions [J].
Qin, SX ;
Rottman, JB ;
Myers, P ;
Kassam, N ;
Weinblatt, M ;
Loetscher, M ;
Koch, AE ;
Moser, B ;
Mackay, CR .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :746-754
[45]   Strong expression of CD134 (OX40), a member of the TNF receptor family, in a T helper 2 type cytokine environment [J].
Roos, A ;
Schilder-Tol, EJM ;
Weening, JJ ;
Aten, J .
JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 64 (04) :503-510
[46]  
RYFFEL B, 1991, AM J PATHOL, V139, P7
[47]   Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells [J].
Sallusto, F ;
Mackay, CR ;
Lanzavecchia, A .
SCIENCE, 1997, 277 (5334) :2005-2007
[48]   STEPWISE DEVELOPMENT OF CHROMOSOMAL-ABNORMALITIES IN ANGIOIMMUNOBLASTIC LYMPHADENOPATHY [J].
SCHLEGELBERGER, B ;
FELLER, A ;
GODDE, E ;
GROTE, W ;
LENNERT, K .
CANCER GENETICS AND CYTOGENETICS, 1990, 50 (01) :15-29
[49]   ANAPLASTIC LARGE-CELL LYMPHOMAS EXPRESSING THE NOVEL CHIMERIC PROTEIN P80(NPM/ALK) - A DISTINCT CLINICOPATHOLOGICAL ENTITY [J].
SHIOTA, M ;
NAKAMURA, S ;
ICHINOHASAMA, R ;
ABE, M ;
AKAGI, T ;
TAKESHITA, M ;
MORI, N ;
FUJIMOTO, J ;
MIYAUCHI, J ;
MIKATA, A ;
NANBA, K ;
TAKAMI, T ;
YAMABE, H ;
TAKANO, Y ;
IZUMO, T ;
NAGATANI, T ;
MOHRI, N ;
NASU, K ;
SATOH, H ;
KATANO, H ;
FUJIMOTO, J ;
YAMAMOTO, T ;
MORI, S .
BLOOD, 1995, 86 (05) :1954-1960
[50]   The T cell B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response [J].
Stuber, E ;
Strober, W .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :979-989